On December 23, 2022, Alpha-1 Canada was informed that the Conference of Deputy Ministers of Health authorized Canadian Blood Services to move forward with issuing a request for proposals (RFP) for Health Canada-approved A1-PI products.
An announcement will be shared with the patient community as to which augmentation therapy will be available for Canadian alpha-1 patients in the new year with national access to treatment (outside of Quebec) commencing in Spring 2023.
This has been a five-year journey and no small feat. This could not have been done without the support of the patient community and Alpha-1 Canada sponsors Grifols, CSL Behring, AlphaNet Canada, and Takeda.
Alpha-1 Canada will continue to share information with the patient community as it becomes available in the new year and is incredibly grateful to all of the provincial and territorial government stakeholders and to Canadian Blood Services for working to achieve this huge milestone. Please encourage your friends and families (if they are able) to book an appointment to give blood or plasma: https://www.blood.ca
